• Sector: Industrial
  • Location: Wales
  • Website: www.gtsflexible.com
  • Date of investment: Jul-20
  • GCP board members: Ravi Monteiro, James Blake


  • Specialist manufacturer of adhesives and flexible materials for the automotive, renewables and power generation industries
  • A highly recognised and differentiated brand with over 50 years of technical know-how and experience
  • End uses include flexible circuits used in automotive such as battery interconnect circuits for EVs and laminated busbars for safe and efficient distribution of power in industrial applications

Why we invested

  • GTS has an established and differentiated market position as a manufacturer of specialist technical products
  • Long term, embedded customer relationships with a focus on technical support and product evolution
  • Focus on new product development, technical innovation and quality
  • Well positioned to take advantage of growing end market opportunities, particularly in battery production for electric vehicles, the trends in the shift towards renewable energy and increasing electrification of transportation
  • Backing a highly experienced management team with a robust plan for growth

How we are making a difference

  • GCP funded the entire deal at completion with a flexible capital structure to suit the needs of the business and shareholders, underpinning the deliverability of the deal
  • Our investment will enable GTS to scale up its operations and processes, explore strategic expansion and bolster the sales, marketing and finance functions to maximise the significant growth opportunities in the markets that GTS serves

“The investment is a key milestone in the development of GTS and we are delighted to be working with GCP in the execution of our strategic plans. GCP has a strong track record of supporting specialist manufacturing businesses which they demonstrated by working with us during challenging macro conditions caused by the outbreak of Coronavirus. We have a strong cultural fit with the GCP team and we look forward to working together through the next phase of our journey.”

Chris Burgess, MD